Stephan Stilgenbauer

机构：Universität Ulm, University Hospital Ulm, Technische Hochschule Ulm · ORCID：0000-0002-6830-9296

发表论文 1286 篇 · 总被引 77238 次 · h-index 130

代表论文

• Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18–65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network (2026 · The Lancet · 被引 9)
• Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcomes analysis of the CLL13/GAIA trial (2026 · Blood · 被引 7)
• High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial (2026 · The Lancet · 被引 3)
• Ibrutinib for early-stage CLL: genetic risk factors and treatment outcome in the GCLLSG CLL12 trial (2026 · Blood · 被引 1)
• Autoantibodies to IL-1Ra and PGRN in severe COVID-19 are associated with inflammation-induced hyperphosphorylated antigen isoforms (2026 · Nature Communications · 被引 1)
• In‐frame variants in TP53 gene identified in adult leukemia samples are predominantly deleterious: a study of the TP53 Network of Education and Research Initiative on CLL (2026 · The Journal of Pathology)